Converge Bio
Converge Bio is a generative AI platform focused on accelerating drug discovery and development. Utilizing large language models trained on biological and chemical data, the company aids biotech and pharmaceutical firms in discovering and developing more effective drugs in a shorter timeframe.
Leadership & Board
- Current Number of Employees
- 59
- Current LinkedIn Followers
- 7,188
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $31M
- Total Funding Rounds
- 2
- Latest Funding Amount
- $25M
- Latest Funding Round
- Series A
- Post-Money Valuation
- ―
Company Momentum Positive
Converge Bio LinkedIn following is increasing, signaling rising market interest, but its workforce is shrinking indicating potential contraction.
Employee Trend
Converge Bio had 59 employees as of October 12, 2026. The number of employees increased by 4 (7.27%) week-over-week.
Social Trend
Converge Bio had 7,188 followers as of October 12, 2026. The number of followers increased by 181 (2.58%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jan 13, 2026 | Series A | $25.00M | ― |
| Aug 14, 2025 | Seed Round | $5.50M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Bessemer Venture Partners | Series A |
| TLV Partners | Series A |
| Vintage Investment Partners | Series A |
| executives from OpenAI | Series A |
| Saras Capital | Series A |
| Executives from Meta | Series A |
| Executives from Wiz | Series A |
| TLV Partners | Seed Round |
Similar Companies
A snapshot of private companies similar to Converge Bio, helping you discover and navigate related company profiles.
Related News and Analysis
